[Chronic renal insufficiency. Elevated levels of the active metabolite (3-hydroxyquinidine) of quinidine]. 1982

R Camsonne, and M A Moulin, and J P Ryckelynck, and P Mignot, and F Albessard, and M Perault, and M C Bigot, and O Richard

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D011802 Quinidine An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission. Adaquin,Apo-Quinidine,Chinidin,Quincardine,Quinidex,Quinidine Sulfate,Quinora,Apo Quinidine,Sulfate, Quinidine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R Camsonne, and M A Moulin, and J P Ryckelynck, and P Mignot, and F Albessard, and M Perault, and M C Bigot, and O Richard
January 1991, DICP : the annals of pharmacotherapy,
R Camsonne, and M A Moulin, and J P Ryckelynck, and P Mignot, and F Albessard, and M Perault, and M C Bigot, and O Richard
October 1988, British journal of clinical pharmacology,
R Camsonne, and M A Moulin, and J P Ryckelynck, and P Mignot, and F Albessard, and M Perault, and M C Bigot, and O Richard
September 1987, Obstetrics and gynecology,
R Camsonne, and M A Moulin, and J P Ryckelynck, and P Mignot, and F Albessard, and M Perault, and M C Bigot, and O Richard
January 1984, Therapie,
R Camsonne, and M A Moulin, and J P Ryckelynck, and P Mignot, and F Albessard, and M Perault, and M C Bigot, and O Richard
February 1987, American heart journal,
R Camsonne, and M A Moulin, and J P Ryckelynck, and P Mignot, and F Albessard, and M Perault, and M C Bigot, and O Richard
April 1980, The Journal of pharmacology and experimental therapeutics,
R Camsonne, and M A Moulin, and J P Ryckelynck, and P Mignot, and F Albessard, and M Perault, and M C Bigot, and O Richard
March 1987, The American journal of cardiology,
R Camsonne, and M A Moulin, and J P Ryckelynck, and P Mignot, and F Albessard, and M Perault, and M C Bigot, and O Richard
January 1979, Clinica chimica acta; international journal of clinical chemistry,
R Camsonne, and M A Moulin, and J P Ryckelynck, and P Mignot, and F Albessard, and M Perault, and M C Bigot, and O Richard
May 1979, Acta endocrinologica,
R Camsonne, and M A Moulin, and J P Ryckelynck, and P Mignot, and F Albessard, and M Perault, and M C Bigot, and O Richard
January 1980, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!